Trial Profile
Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms RITUXANFMD
- 25 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 20 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrial.gov record.
- 16 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrial.gov record.